Curebound is a San Diego-based 501c3 philanthropic organization that raises and invests strategic funding in translational cancer research projects aimed at accelerating new discoveries to clinical application.
Curebound is headquartered in San Diego amidst a unique combination of three NCI-cancer centers, clinical care hospitals, biotech companies, venture capital investors, philanthropic networks, and most importantly- a regional culture that embraces the spirit of collaboration.
This ecosystem positions San Diego and Curebound at the forefront of discovery - bringing genomic medicine, new technologies and clinical trials to market and presents an unprecedented opportunity for research collaboration. We believe that the next decade will be critical to the development of sophisticated, personalized approaches in the way we prevent, treat and ultimately find cures for cancer.
Curebound is committed to investing $100 million into collaborative cancer research in San Diego to make the vision of cures in our lifetime a reality.
Mobilize San Diego to accelerate cures for cancer in
Curebound unites two highly respected cancer organizations, Padres Pedal the Cause and the Immunotherapy Foundation, both of which were founded by families whose lives were changed by cancer.
Padres Pedal the Cause was founded by Bill Koman, a two-time lymphoma survivor, and his wife Amy. Deeply grateful for the life- saving care that Bill received, the Koman family is committed to ensuring the same outcome for others. In 2013, Amy and Bill Koman created Padres Pedal the Cause, a cancer fundraising cycling challenge operated in partnership with the San Diego Padres that has raised more than $15 million and funded 73 collaborative research projects in San Diego, including 6 clinical trials. ‘Padres Pedal’ is an outgrowth of Pedal the Cause St. Louis (founded by the Komans in 2009), which has raised and donated over $32 million to fund 168 innovative research grants at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
In 2015, Ralph and Fernanda Whitworth established the Immunotherapy Foundation (IF) to accelerate precision cancer immunotherapy research into better treatments for patients. A year later, Ralph lost his battle with cancer, but his vision lives on through IF’s work. In just six years, IF has contributed over $5.5M to promising cancer research, cancer prevention and patient support initiatives. Funds from IF helped to seed and operationalize the Advanced Cell Therapy Lab and enabled the creation of the San Diego Center for Precision Immunotherapy, both as UC San Diego. IF worked to create an HPV cancer prevention curriculum for community health workers, and supported cancer immunotherapy summits for patients and caregivers.
These two organizations, and their founders, share the belief that cures are possible and a vision of a world without cancer.
We are grateful for the visionary leadership of Curebound’s growing circle of founding investors who believe firmly that cures are possible and that together we can change the trajectory of cancer for the next generation. Curebound is made possible through the support and extraordinary generosity of these individuals and organizations:
Cindy & Larry Bloch
Wanda & Cam Garner
Sally & John Hood
Amy & Bill Koman
Roberta & Malin Burnham
Shamala & Raghu Saripalli
Denise & James Herbst
Conrad Prebys Foundation
Franci & Scott Free
Elaine Galinson & Herb Solomon
Melissa & Chris Tresse
Pardee Family Foundation
Jean Wickersham & Donald Kearns
Sheryl & Kirk Lester
Gifts made by December 31, 2022 will be recognized as members of the Founding Fund.
For more information about making a Founder’s Fund investment, please reach out to Christina Jordan at email@example.com
CEO, Endeavor Biomedicines
John Hood is the founder or co-founder of Endeavor Biomedicines, Impact Biomedicines, Neuronomix and Samumed. Currently, John is CEO and Executive Chairman of Endeavor Biomedicines, a company funded in January in 2021 to develop novel therapeutics for Idiopathic Pulmonary Fibrosis and oncology.
Managing Director, Red Tree Venture Capital
Dr. Edwards is a Managing Director at Red Tree Venture Capital and part of the founding investment team. Prior to joining Red Tree, he helped found Medicxi (a therapeutics focused venture fund) where he was most recently a partner in the London office. Jon began his venture capital career at Index Ventures in Switzerland. Before moving to Europe, Jon was a life sciences strategy consultant at ClearView Healthcare Partners based in Boston.
CEO & Co-Founder Metacrine, Inc.
Richard A. Heyman, Ph.D., is a scientist and entrepreneur with more than 25 years of experience in the building of biotech and life science companies. He is the co-founder and Chairman of ORIC Pharmaceuticals, which is developing drugs to overcome resistance in cancer. He currently is the Chairman and co-founder of Metacrine Inc. and serves as Chairman of Amunix Pharmaceuticals, Vividion Therapeutics and PMV Pharma.
Managing Director, RiverVest Venture Partners
Nancy Hong has been a managing director at the life science-focused venture capital firm RiverVest since 2016, investing in both biopharmaceutical and medical device opportunities. She previously served on the board at Xilio Therapeutics (NASDAQ: XLO). Currently, Nancy is a member of the Board of Directors at Scout Bio, SeQure Dx, BlueJay Therapeutics, and Biolinq.
Lita Annenberg Hazen Professor of Chemistry, The Scripps Research Institute
Dr. Kelly received his PhD in organic chemistry from the University of North Carolina at Chapel Hill, USA, in 1986, and performed post-doctoral research at The Rockefeller University, New York, USA, in the area of chemistry and biology. The Kelly group’s research in the field of chemical biology focuses on uncovering protein structure–function–folding relationships and on understanding the etiology of protein misfolding and/or aggregation diseases. He uses this information to develop novel therapeutic strategies.
Senior Associate Dean and Associate Vice Chancellor for Cancer Research and Care, Moores Cancer Center at UC San Diego Health
Scott M. Lippman, MD, brings more than 25 years of experience as principal investigator of translational research involving investigator-initiated clinical trials and maintains an active clinical practice. As a clinician, he is well-respected by his peers, with recognition in every major “Top Doctor” listing including U.S. News & World Report.
Director, Sanford Burnham Prebys Cancer Center; Jeanne and Gary Herberger Leadership Chair in Cancer Research
Ze’ev Ronai is an expert in cancer biology, holding a PhD in Tumor Immunology from the Hebrew University in Jerusalem, Israel. Following postdoctoral research at the Columbia University, Ronai was tenured at Mount Sinai School of Medicine in New York. Subsequently, he joined Sanford Burnham Prebys Medical Discovery Institute in Ja Jolla, CA where he served as Program Director and Deputy Director to the Cancer Center, and as the Scientific Director of the La Jolla site.
Director, Salk Institute Cancer Center Professor of Molecular and Cell Biology Laboratory William R. Brody Chair
Reuben Shaw is the Director of the Salk NCI-Designated Cancer Center and brings more than 25 years of research experience working on oncogene and tumor suppressor pathways in research and more than 15 years on the faculty of the world-renowned Salk Institute for Biological Studies in La Jolla, CA.
Partner, LYZZ Capital
Mr. Turner is cofounder and Executive Chair of Onchilles and a partner of LYZZ Capital. Mr. Turner has more than 20 years of experience in founding, operating, fundraising for, and exiting life science companies. Before joining Onchilles, Mr. Turner was a venture partner at Avalon Ventures. During his time at Avalon, he served as the founding CEO and director of both Synthorx, Inc. (acquired by Sanofi) and Cellular Approaches, Inc.
Pediatric Hematologist/Oncologist, Rady Children’s Hospital San Diego
Dr. Paula Aristizabal is a hematologist-oncologist at Rady Children's Hospital-San Diego and an associate Professor of Pediatrics in the Division of Pediatric Hematology/Oncology at UC San Diego. She completed her fellowship in pediatric hematology and oncology at UC San Diego School of Medicine and a Master of Advanced Studies in clinical research at UC San Diego.
Vice President, Head of Illumina Open Innovation
Dr. Van Zeeland has been leading innovative genomics research and development programs for more than 15 years and is currently Vice President and Head of Illumina Open Innovation after holding various executive roles within Product Development at Illumina.Previously she was co-founder and CEO of Cypher Genomics, a cloud-based genome interpretation company, which sold to Human Longevity, Inc. (HLI) in 2015.
Associate Director, Clinical Science; Chief, Division of Hematology-Oncology Moores Cancer Center at UC San Diego Health
Ezra Cohen, MD, is a board-certified oncologist and an internationally renowned cancer researcher. He cares for patients with all types of head and neck cancers, including esophageal, thyroid and salivary gland cancers.
Dr. Cohen serves as co-director of UC San Diego Health's Precision Immunotherapy Clinic, which offers the most promising investigational immunotherapy treatments for many types of cancer, including head and neck cancers. At UC San Diego Health's Moores Cancer Center, he is associate director for translational science and the leader of the Solid Tumor Therapeutics research program.
Chief Scientific Officer, La Jolla Institute for Immunology
Dr. Kronenberg is an internationally recognized scientist and one of the most highly cited immunologists in the world. This distinction is held by less than one half of one percent of all publishing scientific authors.
He received his Ph.D. from the California Institute of Technology in 1983, and stayed on to complete his postdoctoral work before joining the faculty of the UCLA School of Medicine in 1986. At UCLA, he rose through the ranks to full professor. In 1997, he joined La Jolla Institute and went on to lead the organization as President and CEO from 2003 to 2021. Dr. Kronenberg now serves as LJI's Chief Scientific Officer and conducts an active research program.
CEO, Koman Group; Founder, Padres Pedal the Cause
Bill Koman has been active in real estate development and investment for more than 35 years. Under his leadership, The Koman Group has developed over $2 billion in new projects since 2000 throughout the Midwest region with a portfolio including large office parks, multifamily, and mixed-use projects from his home city of St. Louis. In 2012, Bill relocated to San Diego and established West of 5, a southern California real estate platform with two other industry-leading partners.
Founder, Immunotherapy Foundation
Fernanda “Fe” Whitworth is a mother, community philanthropist, entrepreneur and co-founder of Immunotherapy Foundation with her beloved husband, Ralph V. Whitworth. Born in Sao Paulo, Brazil, Fe moved to the United States in 2004 to attend San Diego State University with a major in Business. She is the co-founder of Alchemy Fine Home, an online interior design/décor business that curates the finest home décor from around the world.
Private Investor & Former Chairman TransWestern Publishing Company
Larry is a private investor and former Executive Chairman of TransWestern Publishing Company, a private-equity sponsored directory publishing company. Early in his career, Mr. Bloch was a Managing Director at Smith Barney; Vice President-Corporate Finance at Thomson McKinnon Securities; and Senior Vice President and CFO of Lanxide Corporation. He has over 35 years of experience in public and private finance, mergers and acquisitions, corporate and non-profit governance.
CEO, San Diego Regional Economic Development Corporation
Mark Cafferty serves as President and Chief Executive Officer of the San Diego Regional Economic Development Corporation. Cafferty has spent more than 25 years designing systems to support career advancement and economic opportunity for American workers. He has served in numerous public-sector leadership positions and has been sought as a consultant on workforce development efforts throughout the country. Serving on workforce committees for the current and recent Mayors and former Governor Jerry Brown, he is a trusted nonpartisan committed to helping leaders shape a more equitable and all-encompassing economic recovery.
CEO, Boxer Capital
Aaron Davis is Co-Founder and Chief Executive Officer of Boxer Capital, LLC. In 2005, after joining Tavistock Group as Portfolio Manager, Mr. Davis scaled Tavistock Group’s public healthcare investing activities and formed Boxer Capital. Mr. Davis leads the firm’s research team, deal structuring, and portfolio management.
CEO & Co-Founder Metacrine, Inc.
Richard A. Heyman, Ph.D., is a scientist and entrepreneur with more than 25 years of experience in the building of biotech and life science companies. He is the co-founder and Chairman of ORIC Pharmaceuticals, which is developing drugs to overcome resistance in cancer.
CEO, Endeavor Biomedicines
John Hood is the founder or co-founder of Endeavor Biomedicines, Impact Biomedicines, Neuronomix and Samumed. Currently, John is CEO and Executive Chairman of Endeavor Biomedicines, a company funded in January in 2021 to develop novel therapeutics for Idiopathic Pulmonary Fibrosis and oncology. Prior to that he was the Founder and Chief Executive Officer of Impact Biomedicines, a company that was acquired by Celgene in 2018 and whose lead asset has subsequently been approved in the US and EU for treatment of myelofibrosis.
Deputy Director, UC San Diego Moores Cancer Center Professor of Medicine and Chief, Division of Regenerative Medicine
Catriona “Cat” Jamieson, MD, Ph.D. is a leading physician-scientist in the cancer stem cell biology field. She is a Professor of Medicine, the Koman Family Presidential Endowed Chair in Cancer Research, Deputy Director of the Moores Cancer Center and the Director of the Sanford Stem Cell Clinical Center at the University of California San Diego (UCSD). Dr. Jamieson is the Director of the California Institute for Regenerative Medicine (CIRM) Alpha Stem Cell Clinic at UCSD, which provides infrastructure to accelerate the bench to bedside development and implementation of cancer stem cell targeted and cellular immunotherapy trials for hematologic and other malignancies.
President Emeritus, Rady Children’s Hospital
After serving as President and Chief Executive Officer of Rady Children’s Hospital and Health Center, Dr. Kearns transitioned to the newly created role of President Emeritus in 2019. Rady Children’s is a 551- bed pediatric care facility providing the largest source of comprehensive pediatric medical services in San Diego, Southern Riverside and Imperial counties and the region’s only designated pediatric trauma center. As one of the premier pediatric hospitals in the nation, Rady Children’s is ranked by U.S. News & World Report as one of America’s best surveyed.
CEO, Lofta Inc.
Jay has been an effective civic and business leader in the San Diego community for over 30 years. After graduating from the University of Iowa, he moved to California and pursued the path of “serial entrepreneur.” In doing so, he has built successful businesses in the wireless communications and residential mortgage spaces. In 2017, Jay launched Lofta, a national technology company revolutionizing the way sleep apnea is diagnosed and treated. In addition to these pursuits, Mr. Levitt manages an ownership interest in a substantial portfolio of commercial real estate throughout the country.
Principal, Bernstein Private Wealth Management
Chris joined Bernstein’s San Francisco office in 2001. He was made a Principal of the firm and relocated to help launch the San Diego practice in 2005, which currently manages some $3B in client assets. He advises high net worth families and charitable foundations on strategies involving investment planning and strategic asset allocation. Previously, he was a Director at Vividence, an Internet consulting firm, where he managed the strategic client group.
Partner, LYZZ Capital Advisors
Mr. Turner is cofounder and Executive Chair of Onchilles and a partner of LYZZ Capital. Mr. Turner has more than 20 years of experience in founding, operating, fundraising for, and exiting life science companies. Before joining Onchilles, Mr. Turner was a venture partner at Avalon Ventures. During his time at Avalon, he served as the founding CEO and director of both Synthorx, Inc. (acquired by Sanofi) and Cellular Approaches, Inc. Prior to those roles, Mr. Turner was the founding chairman and CEO of RQx Pharmaceuticals (acquired by Genentech).
Chairman, Burnham Foundation
Malin Burnham has been Chairman of John Burnham & Company Insurance and Burnham Real Estate and has remained involved since 1949. In 2008, Burnham Real Estate was acquired by Cushman & Wakefield. In addition to his involvement with the Burnham Companies, he has been active as a board member of several major corporations.
Anne Marbarger is the CEO of Curebound, a San Diego-based organization committed to accelerating cures for cancer by funding collaborative research among San Diego’s top cancer research centers. Curebound is well on its way to a bold goal of raising and investing $100 million in game-changing research projects that show promise of translating basic discoveries to clinical and commercial stages.
Professor and Dean, Herbert Wertheim School of Public Health and Human Longevity Science
Cheryl A. M. Anderson is a Professor and Dean of the University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science. Dr. Anderson's research focuses on nutrition and chronic disease prevention in underserved populations using observational epidemiologic study designs, randomized clinical trials, and implementation science.
Chief Executive Officer
Chief Development Officer
Director, Communications & Creative
Manager, Programs & Special Events
Event Director Padres Pedal the Cause
Manager, Development Padres Pedal the Cause